In a private stock placement, Ilypsa generated $36 million from venture investors, including US Venture Partners, Johnson & Johnson Development, and Delphi Ventures. Ilypsa will use the funds to complete preclinical and initiate clinical development of two compounds aimed at chronic kidney disease and metabolic disorders.
- read this press release for more